Israel Recalls Similac Infant Formula Batch After Quality Complaint

Israel's Ministry of Health has ordered the temporary recall of a specific batch of Similac infant formula, identified by lot number 89203N201, which was exclusively distributed to medical facilities nationwide. This precautionary measure was initiated following a single complaint regarding the product's quality. The ministry emphasized that this batch did not enter general retail and was only supplied to hospital wards. No adverse health effects in infants have been reported thus far.

Abbott, the manufacturer, is reportedly arranging for the replacement of the affected batch with safe alternatives. The recall is strictly limited to the specified lot, with all other Similac products and batches remaining unaffected and safe for use.

In a separate advisory, the Ministry of Health also warned the public against purchasing or consuming the weight-loss product G-Slim. This warning follows laboratory tests that detected sibutramine, a pharmaceutical substance with significant health risks and restricted or banned in many countries, including Israel. The concentration of sibutramine found in G-Slim capsules was more than triple that of previously recalled products.

Concerns about G-Slim's safety were medically confirmed when a consumer experienced chest pains and rapid heart rate after taking the product, requiring emergency medical attention. The ministry strongly advises against the use of G-Slim and urges consumers to exercise caution with unregulated weight-loss products that may contain undeclared ingredients.